𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Treatment of refractory Hodgkin's disease with high-dose cytosine arabinoside and mitoxantrone in combination. Results of a clinical phase II study of the German Hodgkin study group

✍ Scribed by Wolfgang Hiddemann; Norbert Schmitz; Michael Pfreundschuh; Karl-Heinz Pflüger; Jürgen Ollech-Chwoyka; Christian Tirier; Georg Maschmeyer; Hartmut Kirchner; Thomas Wagner; Peter Koch; Elmar Dahmen; Walter Fiedler; Lorenz Trümper; Volker Diehl

Publisher
John Wiley and Sons
Year
1990
Tongue
English
Weight
570 KB
Volume
66
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

High antileukemic activity of sequential
High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias : Results of a clinical Phase II study
✍ Wolfgang Kern; Eberhard Schleyer; Michael Unterhalt; Bernhard Wörmann; Thomas Bü 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 147 KB 👁 2 views

Department of Heremission whereas 5 patients (23%) succumbed to early death and 3 patients (14%) matology and Oncology, Go ¨ttingen, Germany. did not respond. Blood counts recovered at a median of 33.5 days after the start 2 Westfa ¨lische Wilhelms University, Department of treatment and complete r

Treatment of refractory acute myeloid le
Treatment of refractory acute myeloid leukemia with mAMSA and VP 16-213 in combination: Results of a clinical phase I/II study
✍ Wolfgang Hiddemann; Dieter Urbanitz; Peter Preusser; Wolf Achterrath; Thomas Büc 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 482 KB

Twenty patients with refractory AML were treated with mAMSA and VP 16-2 13 in combination to assess the toxicity and anti-leukemic activity of the two-drug regimen. Refractoriness was defined according to the response to induction therapy consisting of 6-thioguanine, cytosine arabinoside and daunoru

Phase II trial of etoposide and cis-diam
Phase II trial of etoposide and cis-diaminodichloro-platinum in patients with refractory and relapsed Hodgkin's disease: Cancer and leukemia group B (CALGB) study 8353
✍ Rybak, Mary Ellen ;McCarroll, Kathleen ;Kaplan, Richard J. ;Propert, Kathleen J. 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 394 KB

## Abstract A phase II study was conducted by the Cancer and Leukemia Group B (CALGB) in patients with refractory and relapsed Hodgkin's disease (HD) to assess the activity of the combination of etoposide and cis‐platin. Twenty‐seven patients were entered; 22 were evaluated for this report. Treatme